


CDK9-IN-27

Cat. No.:	HY-155177
Molecular Formula:	C ₂₃ H ₁₈ ClN ₅ O ₃
Molecular Weight:	447.87
Target:	CDK
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CDK9-IN-27 (Compound 6a) is a CDK9 inhibitor (IC ₅₀ : 0.424 μM). CDK9-IN-27 induces apoptosis and cell cycle arrest at S stage. CDK9-IN-27 has cytotoxic action against HepG2, HCT-116 and MCF-7 cell lines, with IC ₅₀ s of 10.31-40.34 μM. CDK9-IN-27 can be used for cancer research ^[1] .
IC ₅₀ & Target	0.424 μM (CDK9) ^[1]

REFERENCES

[1]. Husseiny EM, et al. Aminopyridone-linked benzimidazoles: a fragment-based drug design for the development of CDK9 inhibitors. Future Med Chem. 2023 Aug 16.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA